Stock Alarm Pro

Gilead Sciences, Inc.GILDNASDAQ

$0.00+0.00 (+0.00%)

CLOSED

Prev —|Open —|Day —–—|Vol —

Overview News Chart Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 72% recommend buying.

Consensus Rating

Buy

25 analysts·High coverage

72%

Rating Distribution

Strong Buy

00%

Buy

1872%

Hold

728%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see modest upside — consensus target 6% higher.

Bear Case

$105.00

-16%

Base Case

$132.77

+6%

Bull Case

$151.00

+21%

Price Range25 analysts

Low

Consensus

High

$105.00

$151.00

Current Target

Current Price

$124.91

Upside to Target

$7.86

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2025E$8.16(17 analysts)

P/E19x

Current: 19.1x

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Recent Analyst Actions

Dec 29, 2025Bernstein

Bernstein Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$135.00

+8.4%from $124.56

Dec 15, 2025Wolfe Research

Gilead Sciences (GILD) PT Raised to $150 at Wolfe Research

Target:$150.00

+24.6%from $120.41

Dec 12, 2025Morgan Stanley

Gilead price target raised to $151 from $147 at Morgan Stanley

Target:$151.00

+22.6%from $123.21

Dec 10, 2025HSBC

Gilead price target raised to $133 from $110 at HSBC

Target:$133.00

+11.4%from $119.36

Nov 25, 2025BMO Capital

BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$135.00

+5.8%from $127.57

Nov 24, 2025Truist Financial

Gilead assumed with a Buy at Truist

Target:$140.00

+9.5%from $127.91

Nov 20, 2025Mizuho Securities

Gilead price target raised to $140 from $131 at Mizuho

Target:$140.00

+12.0%from $124.99

Oct 31, 2025Morgan Stanley

Gilead price target raised to $147 from $143 at Morgan Stanley

Target:$147.00

+24.0%from $118.52

Oct 31, 2025RBC Capital

Gilead price target raised to $105 from $100 at RBC Capital

Target:$105.00

-11.3%from $118.44

Oct 31, 2025Wells Fargo

Gilead price target raised to $145 from $140 at Wells Fargo

Target:$145.00

+22.4%from $118.44

Oct 9, 2025Cantor Fitzgerald

Gilead price target raised to $135 from $129 at Cantor Fitzgerald

Target:$135.00

+14.2%from $118.25

Oct 6, 2025Wells Fargo

Wells says Biktarvy patent settlement 'big deal' for Gilead at, $6-$12 upside

Target:$140.00

+24.2%from $112.69

Aug 11, 2025Deutsche Bank

Gilead price target raised to $135 from $120 at Deutsche Bank

Target:$135.00

+13.6%from $118.83

Aug 8, 2025Robert W. Baird

Gilead price target raised to $108 from $100 at Baird

Target:$108.00

-9.6%from $119.41

Aug 8, 2025Morgan Stanley

Gilead price target raised to $143 from $135 at Morgan Stanley

Target:$143.00

+19.8%from $119.41

Jul 14, 2025Leerink Partners

Gilead price target raised to $114 from $105 at Leerink

Target:$114.00

+1.7%from $112.09

Jun 18, 2025Morgan Stanley

Morgan Stanley says FDA approval of Yeztugo 'an expected positive' for Gilead

Target:$135.00

+25.0%from $108.00

Apr 22, 2025Cantor Fitzgerald

Gilead assumed at Overweight from Neutral at Cantor Fitzgerald

Target:$125.00

+18.5%from $105.51

Mar 11, 2025Morgan Stanley

Gilead price target raised to $130 from $123 at Morgan Stanley

Target:$130.00

+13.6%from $114.43

Mar 5, 2025Johnson Rice

Gilead price target raised to $126 from $116 at BofA

Target:$126.00

+9.1%from $115.44

Mar 4, 2025Oppenheimer

Gilead price target raised to $132 from $115 at Oppenheimer

Target:$132.00

+15.0%from $114.74

Jan 7, 2025RBC Capital

Gilead price target lowered to $83 from $84 at RBC Capital

Target:$83.00

-8.4%from $90.63

Nov 7, 2024Piper Sandler

Gilead Sciences (GILD) PT Raised to $105 at Piper Sandler

Target:$105.00

+16.6%from $90.09

Oct 21, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$94.00

+9.2%from $86.11

Oct 21, 2024Leerink Partners

Leerink Partners Upgrades Gilead Sciences (GILD) to Outperform

Target:$96.00

+10.7%from $86.72

Oct 18, 2024Morgan Stanley

Gilead bladder cancer withdrawal 'expected negative,' says Morgan Stanley

Target:$84.00

-3.5%from $87.07

Sep 23, 2024Jefferies

Jefferies on Gilead Sciences (GILD): 'Competitor Dato surprise setback in breast cancer, new incremental (+) for GILD'

Target:$95.00

+13.4%from $83.76

Sep 12, 2024Goldman Sachs

Goldman Sachs Reiterates Neutral Rating on Gilead Sciences (GILD)

Target:$71.00

-14.3%from $82.85

Sep 12, 2024Morgan Stanley

Gilead lenacapavir data 'an expected positive,' says Morgan Stanley

Target:$79.00

-4.4%from $82.63

Sep 11, 2024Piper Sandler

Piper Sandler Reiterates Overweight Rating on Gilead Sciences (GILD)

Target:$95.00

+18.9%from $79.93

Aug 14, 2024Truist Financial

Gilead Sciences (GILD) PT Raised to $83 at Truist Securities

Target:$83.00

+12.0%from $74.14

Aug 9, 2024BMO Capital

Gilead Sciences (GILD) PT Raised to $85 at BMO Capital

Target:$85.00

+12.4%from $75.59

Aug 9, 2024RBC Capital

Gilead Sciences (GILD) PT Raised to $72 at RBC Capital

Target:$72.00

-4.7%from $75.59

Jul 8, 2024Raymond James

Raymond James Upgrades Gilead Sciences (GILD) to Outperform

Target:$93.00

+37.2%from $67.76

Jun 24, 2024Jefferies

Gilead price target raised to $85 from $80 at Jefferies

Target:$85.00

+19.3%from $71.24

Jun 20, 2024Robert W. Baird

Baird on Gilead Sciences (GILD): 'Incrementally positive on clinical data'

Target:$80.00

+15.6%from $69.21

Jun 17, 2024Mizuho Securities

Gilead Sciences (GILD) GS-4571 Intended for NASH Not Obesity - Mizuho

Target:$90.00

+39.5%from $64.52

Jun 14, 2024RBC Capital

RBC Capital Reiterates Sector Perform Rating on Gilead Sciences (GILD)

Target:$74.00

+14.4%from $64.68

May 20, 2024BMO Capital

BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)

Target:$80.00

+17.8%from $67.90

Apr 24, 2024HSBC

HSBC Upgrades Gilead Sciences (GILD) to Hold

Target:$69.00

+2.9%from $67.08

Feb 14, 2024RBC Capital

Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields

Target:$76.00

+3.4%from $73.53

Sep 27, 2023RBC Capital

Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields

Target:$84.00

+10.7%from $75.90

Sep 8, 2023Bank of America Securities

Gilead Sciences Shares Trade Higher After Bullish Analyst Upgrades Stock

Target:$95.00

+25.1%from $75.92

Feb 3, 2023Leerink Partners

SVB Leerink Maintains Market Perform on Gilead Sciences, Raises Price Target to $91

Target:$91.00

+7.5%from $84.64

Feb 3, 2023Piper Sandler

Piper Sandler Maintains Overweight on Gilead Sciences, Raises Price Target to $112

Target:$112.00

+37.6%from $81.39

Jan 3, 2023Wells Fargo

Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $90

Target:$90.00

+5.3%from $85.46

Dec 1, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $81

Target:$81.00

-8.3%from $88.34

Oct 31, 2022Barclays

Gilead upgraded to Equal Weight from Underweight at Barclays

Target:$76.00

-4.1%from $79.27

Oct 28, 2022Truist Financial

Gilead upgraded to Buy from Hold at Truist

Target:$91.00

+29.6%from $70.20

Oct 28, 2022Robert W. Baird

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX), Gilead Sciences (NASDAQ: GILD) and InMode (NASDAQ: INMD)

Target:$69.00

-13.0%from $79.27

Sep 15, 2022Truist Financial

Truist Securities Maintains Hold on Gilead Sciences, Raises Price Target to $76

Target:$76.00

+17.3%from $64.81

Sep 13, 2022Wells Fargo

Wells Fargo Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $74

Target:$74.00

+11.8%from $66.19

Jul 15, 2022Morgan Stanley

Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $65

Target:$65.00

+4.3%from $62.30

May 23, 2022Leerink Partners

Gilead Sciences (GILD) Stock: $68 Price Target And Market Perform Rating

Target:$68.00

+6.2%from $64.04

May 17, 2022Piper Sandler

Gilead Sciences (GILD) Stock: $69 Price Target From Piper Sandler

Target:$69.00

+9.2%from $63.18

Apr 29, 2022BMO Capital

BMO Capital Maintains Market Perform on Gilead Sciences, Lowers Price Target to $63

Target:$63.00

+5.8%from $59.54

Apr 29, 2022Piper Sandler

Piper Sandler Maintains Neutral on Gilead Sciences, Raises Price Target to $73

Target:$73.00

+21.6%from $60.04

Apr 6, 2022Piper Sandler

Gilead Sciences (GILD) Stock: $71 Price Target From Piper Sandler

Target:$71.00

+16.7%from $60.82

Mar 31, 2022Wells Fargo

Gilead Sciences (GILD) Stock: $63 Price Target And Equal Weight Rating

Target:$63.00

+6.0%from $59.45

Mar 1, 2022Jefferies

Jefferies Thinks Gilead Sciences' Stock is Going to Recover

Target:$80.00

+34.5%from $59.50

Feb 24, 2022Morgan Stanley

Gilead Sciences (GILD) Has an 80% Chance of Trading Higher on this Catalyst - Morgan Stanley

Target:$69.00

+15.3%from $59.85

Feb 24, 2022UBS

Gilead Sciences (GILD) PT Raised to $54 at UBS

Target:$54.00

-9.8%from $59.85

Feb 8, 2022Mizuho Securities

Gilead Sciences (GILD) Stock: $75 Price Target From Mizuho

Target:$75.00

+17.7%from $63.70

Feb 4, 2022Atlantic Equities

Gilead Sciences (GILD) PT Lowered to $62 at Atlantic Equities

Target:$62.00

-1.7%from $63.10

Feb 3, 2022Oppenheimer

Gilead Sciences (GILD) PT Lowered to $90 at Oppenheimer

Target:$90.00

+39.4%from $64.57

Feb 3, 2022Maxim Group

Gilead price target lowered to $84 from $88 at Maxim

Target:$84.00

+30.1%from $64.57

Jan 28, 2022Argus Research

Gilead upgraded to Buy from Hold at Argus

Target:$75.00

+10.3%from $67.99

Dec 6, 2021Goldman Sachs

Gilead initiated with a Neutral at Goldman Sachs

Target:$80.00

+17.8%from $67.94

Nov 19, 2021Wedbush

Gilead Sciences (GILD) PT Raised to $67 at Wedbush

Target:$67.00

-0.2%from $67.14

Apr 29, 2021J.P. Morgan

J.P. Morgan Keeps a Hold Rating on Gilead Sciences (GILD)

Target:$74.00

+21.0%from $61.14